JLE

European Journal of Dermatology

MENU

S-1 in combination with docetaxel as salvage therapy for patients with metastatic extramammary Paget's disease Volume 30, issue 3, May-June 2020

Tables

Authors
1 Department of Dermatology,
2 Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo, 160-8582, Japan

Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that generally arises in the anogenital area, and patients with distant metastases exhibit poor prognosis with a median overall survival (OS) of approximately 1.5 years [1, 2]. To date, several chemotherapy regimens have been used for treating metastatic EMPD, such as low-dose 5-fluorouracil (5-FU) and cisplatin (FP); 5-FU, epirubicin, carboplatin, vincristine, and mitomycin C (FECOM); cisplatin, epirubicin, and paclitaxel (PET); [...]